FIG. 1A



FIG. 1B



FIG. 1C

GGTCAGGGCAAACCTGCCTCCCATTCTACTCAAAGTCATCCCTCTGCTCACAGAGATGGATGCATGTTCTGATTGCCTCT 1360

TTGGAGAAGCTCATCAGAAACTCAAAAGAAGGCCACTGTTTGTCTCACCTACCCATGACCTGAAGCCCCTCCCTGAGTGG 1440

TCCCCACCTTTCTGGACGGAACCACGTACTTTTTACATACATTGATTCATGTCTCACGTCTCCCTAAAAATGCGTAAGAC 1520

CAAGCTGTGCCCTGACCACCCTGGGCCCCTGTCGTCAGGACCTCCTGAGGCTTTGGCAAATAAACCTCCTAAAATGATAA 1600

AAAAAAAAAAAAAAAAAAAAAAAA 1624

FIG. 2A


ATGGATTTCGGACTGGCCCTCCTGCTGGCGGGGCTTCTGGGGCTCCTCCTCGGCCAGTCCCTCCAGGTGAAGCCCCTGCA 80
M D F G L A L L L A G L L G L L L G Q S L Q V K P L Q
GGTGGAGCCCCCGGAGCCGGTGGTGGCCGTGGCCTTGGGCGCCTCGCGCCAGCTCACCTGCCGCCTGGCCTGCGCGGACC 160
V E P P E P V V A V A L G A S R Q L T C R L A C A D
GCGGGGCCTCGGTGCAGTGGCGGGGCCTGGACACCAGCCTGGGCGCGGTGCAGTCGGACACGGGCCGCAGCGTCCTCACC 240
R G A S V Q W R G L D T S L G A V Q S D T G R S V L T
GTGCGCAACGCCTCGCTGTCGGCGGCCGGGACCCGCGTGTGCGTGGGCTCCTGCGGGGGCCGCACCTTCCAGCACACCGT 320
V R N A S L S A A G T R V C V G S C G G R T F Q H T V
GCAGCTCCTTGTGTACGCCTTCCCGGACCAGCTGACCGTCTCCCCAGCAGCCCTGGTGCCTGGTGACCCGGAGGTGGCCT 400
Q L L V T A F P D Q L T V S P A A L V P G D P E V A
GTACGGCCCACAAAGTCACGCCCGTGGACCCCAACGCGCTCTCCTTCTCCCTGCTCGTCGGGGGCCAGGAACTGGAGGGG 480
C T A H K V T P V D P N A L S F S L L V G G Q E L E G
GCGCAAGCCCTGGGCCCGGAGGTGCAGGAGGAGGAGGAGGAGCCCCAGGGGGACGAGGACGTGCTGTTCAGGGTGACAGA 560
A Q A L G P E V Q E E E E E P Q G D E D V L F R V T E

FIG. 2B



FIG. 2C

```
CCGGCCAGGTCGGGATCAGCCCCTCCTGAGTGGCCAGCCTTTCCCCCTGTGAAAGCAAAATAGCTTGGACCCCTTCAAGT  1200
T  G  Q  V  G  I  S  P  S

TGAGAACTGGTCAGGGCAAACCTGCCTCCCATTCTACTCAAAGTCATCCCTCTGTTCACAGAGATGGATGCATGTTCTGA  1280

TTGCCTCTTTGGAGAAGCTCATCAGAAACTCAAAAGAAGGCCACTGTTTGTCTCACCTACCCATGACCTGAAGCCCCTCC  1360

CTGAGTGGTCCCCACCTTTCTGGACGGAACCACGTACTTTTTACATACATTGATTCATGTCTCACGTCTCCCTAAAAATG  1440

CGTAAGACCAAGCTGTGCCCTGACCACCCTGGGCCCCTGTCGTCAGGACCTCCTGAGGCTTTGGCAAATAAACCTCCTAA  1520

AATGAAAAAAAAAAAAAAA  1539
```

FIG. 3A


AGCATGGATCGGGGCCTGGCCCTCCTGCTGGCGGGGCTTCTGGGGCTCCTCCAGCCGGGCTGCGGCCAGTCCCTCCAGGT 80
M D R G L A L L L A G L L G L L Q P G C G Q S L Q V
GAAGCCCCTGCAGGTGGAGCCCCCGGAGCCGGTGGTGGCCGTGGCCCTGGGCGCCTCTCGCCAGCTCACCTGCCGCCTGG 160
K P L Q V E P P F P V V A V A L G A S R Q L T C R L
ACTGCGCGGACCGCGGGGCCACGGTGCAGTGGCGGGGCCTGGACACCAGCCTGGGCGCGGTGCAGTCGGACGCGGGCCGC 240
D C A D R G A T V Q W R G L D T S L G A V Q S D A G R
AGCGTCCTCACCGTGCGCAACGCCTCGCTGTCGGCGGCCGGGACCCGTGTGTGCGTGGGCTCCTGCGGGGGCCGCACCTT 320
S V L T V R N A S L S A A G T R V C V G S C G G R T F
CCAGCACACCGTGCGGCTCCTTGTGTACGCCTTCCCGGACCAGCTGACCATCTCCCCGGCAGCCCTGGTGCCTGGTGACC 400
Q H T V R L L V Y A F P D Q L T I S P A A L V P G D
CGGAGGTGGCCTGTACGGCCCACAAAGTCACGCCTGTGGACCCCAATGCGCTCTCCTTCTCCCTGCTCCTGGGGGACCAG 480
P E V A C T A H K V T P V D P N A L S F S L L L G D Q
GAACTGGAGGGGGCCCAGGCTCTGGGCCCGGAGGTGGAGGAGGAGGAGGAGGAGCCCCACGAGGAGGAGGACGTGCTGTT 560
E L E G A Q A L G P E V E E E E E E P Q E E E D V L F

FIG. 3B

FIG. 3C

```
CTGGTCACAGAGAGGGACGCACATTCTGATTGCCTCCTTTGGAAAGGCTCATCAGAAACTCAAAAGAAGGTGATCGTTTG  1200

TCCCGCCTACCCGTGACCTGGAAGCCCCCGCCCCGCTCGAGTGACCCCTGACTTTCTGGACGGAACCAACGTACTTCTTA  1280

CATATATTGATTGATGTGTCATATCTCCCTAAAATGCGTAAAACCAGCTGTGCCCCGACCACCTTGGGCCCCTGCCATCA  1360

GGACCTCCTGAGGCTTTGGCAAATAAACCTCCTAAAAGGATAGAAACTGAAACTTGTGGCCGGGCGCGGTGGCTCAAGCC  1440

TGTAATCCCAGCACTTTGGGAGGCCGAGGTGGGTGGATCACGAGGTCAGGAGATCGAGACCATCCTGGCTAACCCGTGAA  1520

ACCCCGTCTCTACTAAAAAAATACAAAAATTAGCCGGGAGCGGTGGCGGGCGCCTGTAGTCCCAGCTACTCGGGAGGCTG  1600

AGGCAGGAGAATGGCGTGAACCCGGGAGGCGGAGCTTGCAGTGAGCTGAGATCCGGCCACTGCACTCCAGCCTGGGGGAC  1680

AGAGCGAGACTCCGTCTCAAAAAAAAAAAAAAAAAAAAA  1721
```

FIG. 4A


VCAM-1
Hu MAdCAM-1
Mu MAdCAM-1
Control
0
1
2
3
4
5
RPMI 8866 cells/CHOP Cell
ACT-1 anti-α4β7
MECA-367 anti MAdCAM-1
Control IgG
anti-β1
2G7 anti-VCAM-1

FIG. 4B


Hu MAdCAM-1
Mu MAdCAM-1
VCAM-
Control
0
1
2
3
4
5
JURKAT cells/CHOP Cell
ACT-1 anti-α4β7
MECA-367 anti MAdCAM-1
Control IgG
anti-β1
2G7 anti-VCAM-1

FIG. 5


RPMI Cells/ CHO/P Transfectant
4
3
2
1
0
HuMAd Clone 4
HuMAd Clone 20
Control IgG
Act-1 anti-α4β7

FIG. 6


NH2
NH2
ICAM-1
VCAM-1
VCAM-1
MUCIN
(Polymorphic)
IgA
Region containing repeated 8 amino acid motif
COOH
COOH
C-terminal extension (only in human clones)
human clones
Murine MAdCAM-1
Human MAdCAM-1

FIG. 7A


Inflammation
Score
3
2.5
2
1.5
1
0.5
0
Descending Colon
Ascending Colon
Tissue
Rat IgG2a
FIB-21
FIB-30

FIG. 7B


Structural Damage
Score
3
2.5
2
1.5
1
0.5
0
Descending Colon
Ascending Colon
Tissue
Rat IgG2a
FIB-21
FIB-30

FIG. 8


2
1.5
1
0.5
0
% CPM
H2O
DSS
DSS+IgG2a
DSS+FIB21
DSS+MECA367
DSS+MECA+FIB
Treatment

FIG. 9



FIG. 10



FIG. 11


3
2
Diarrhea
1
Semi-solid
Solid
0
Stool Consistency
Sgo 326-84
Sgo 63-93
Sgo 129-91
Sgo 17-85
Animals
0
2
4
6
8
10
12
14
16
18
20
Time (Days)

FIG. 12


Inflammatory Activity Score
4
3
2
1
0
Sgo 326-84
Sgo 63-93
Sgo 129-91
Sgo 17-85
Animals
-5
-3
0
5
10
20
Time (days)

FIG. 13



FIG. 14



FIG. 15


Absolute Score Change From Day 0
1
0
-1
-2
ACT-1
Irrelevant
Antibody
Day 5
Day 10
Day 20

FIG. 16


ACT-1 Cells (x 10^3/μl)
15
10
5
0
0
2
6
8
10
Time (days)

FIG. 17A



FIG. 17B

FIG. 17C



FIG. 17D





FIG. 17E

FIG. 18


120
110
100
90
80
70
60
% Initial Body Weight
P<.011
P<.015
P<.02
P<.003
P<.0005
P<.0001
P<.0001
0
1
2
3
4
5
6
Months Post Transfer

FIG. 19


p<0.005
p<0.005
15
10
5
0
% CPM Colon/CPM Spleen-fixed Cells
Colon
CD45RB-lo/Rat IgG2a
CD45RB-hi/Rat IgG2a
CD45RB-hi/FIB-504+MECA-367

FIG. 20


80
60
40
20
0
%CPM Colon/CPM Spleen
p<0.037
p<0.032
p<0.031
p<0.034
Colon
CD45RBlo/Rat IgG2a
CD45RBhi/Rat IgG2a
CD45RBhi/FIB-504
CD45RBhi/MECA-367
CD45RBhi/FIB504+MECA367

FIG. 21


500
400
300
200
100
0
Count/Area
p<0.038
p<0.0002
Left Colon
Right Colon
Rat IgG2a
FIB504+MECA367